478 related articles for article (PubMed ID: 20472059)
1. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
Heigoldt U; Sommer F; Daniels R; Wagner KG
Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
[TBL] [Abstract][Full Text] [Related]
2. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
3. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
Tsume Y; Matsui K; Searls AL; Takeuchi S; Amidon GE; Sun D; Amidon GL
Eur J Pharm Sci; 2017 May; 102():126-139. PubMed ID: 28263914
[TBL] [Abstract][Full Text] [Related]
4. Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption.
Shi Y; Gao P; Gong Y; Ping H
Mol Pharm; 2010 Oct; 7(5):1458-65. PubMed ID: 20704265
[TBL] [Abstract][Full Text] [Related]
5. Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability.
Xu L; Luo Y; Feng J; Xu M; Tao X; He H; Tang X
Int J Pharm; 2012 Jan; 422(1-2):9-16. PubMed ID: 22001837
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents.
Matsui K; Tsume Y; Amidon GE; Amidon GL
Mol Pharm; 2015 Jul; 12(7):2418-28. PubMed ID: 25985298
[TBL] [Abstract][Full Text] [Related]
7. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine.
Kostewicz ES; Wunderlich M; Brauns U; Becker R; Bock T; Dressman JB
J Pharm Pharmacol; 2004 Jan; 56(1):43-51. PubMed ID: 14980000
[TBL] [Abstract][Full Text] [Related]
8. Application of an In Vitro Dissolution/Permeation System to Early Screening of Oral Formulations of Poorly Soluble, Weakly Basic Drugs Containing an Acidic pH-Modifier.
Mizoguchi M; Kataoka M; Yokoyama K; Aihara R; Wada K; Yamashita S
J Pharm Sci; 2018 Sep; 107(9):2404-2410. PubMed ID: 29802932
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
10. A novel pH-dependent gradient-release delivery system for nitrendipine II. Investigations of the factors affecting the release behaviors of the system.
Yang M; Cui F; You B; Wang L; Yue P; Kawashima Y
Int J Pharm; 2004 Nov; 286(1-2):99-109. PubMed ID: 15501006
[TBL] [Abstract][Full Text] [Related]
11. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S
Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006
[TBL] [Abstract][Full Text] [Related]
12. Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method.
Qiu Y; Garren J; Samara E; Cao G; Abraham C; Cheskin HS; Engh KR
J Pharm Sci; 2003 Nov; 92(11):2317-25. PubMed ID: 14603516
[TBL] [Abstract][Full Text] [Related]
13. Dissolution test development for complex veterinary dosage forms: oral boluses.
Fahmy R; Marnane B; Bensley D; Hollenbeck RG
AAPS PharmSci; 2002; 4(4):E35. PubMed ID: 12646007
[TBL] [Abstract][Full Text] [Related]
14. Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems.
Phillips DJ; Pygall SR; Cooper VB; Mann JC
J Pharm Pharmacol; 2012 Nov; 64(11):1549-59. PubMed ID: 23058042
[TBL] [Abstract][Full Text] [Related]
15. Self-microemulsifying drug delivery system for improved oral bioavailability of dipyridamole: preparation and evaluation.
Guo F; Zhong H; He J; Xie B; Liu F; Xu H; Liu M; Xu C
Arch Pharm Res; 2011 Jul; 34(7):1113-23. PubMed ID: 21811918
[TBL] [Abstract][Full Text] [Related]
16. A modified physiological BCS for prediction of intestinal absorption in drug discovery.
Zaki NM; Artursson P; Bergström CA
Mol Pharm; 2010 Oct; 7(5):1478-87. PubMed ID: 20734997
[TBL] [Abstract][Full Text] [Related]
17. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
18. Considerations in the development of an in vitro dissolution condition for lacidipine tablets: in vivo pharmacokinetic evaluation.
Sun M; Sun J; He S; Wang Y; Sun Y; Liu X; He Z
Drug Dev Ind Pharm; 2012 Sep; 38(9):1099-106. PubMed ID: 22188158
[TBL] [Abstract][Full Text] [Related]
19. Improved dissolution and pharmacokinetic behavior of dipyridamole formulation with microenvironmental pH-modifier under hypochlorhydria.
Onoue S; Inoue R; Taniguchi C; Kawabata Y; Yamashita K; Wada K; Yamauchi Y; Yamada S
Int J Pharm; 2012 Apr; 426(1-2):61-66. PubMed ID: 22266536
[TBL] [Abstract][Full Text] [Related]
20. In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS Class 2 drugs.
Higashino H; Hasegawa T; Yamamoto M; Matsui R; Masaoka Y; Kataoka M; Sakuma S; Yamashita S
Mol Pharm; 2014 Mar; 11(3):746-54. PubMed ID: 24460473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
